Tutorials
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc

$ 69.40 -1.87 (-2.62%) 01:04 PM EST
P/E:
At Loss
P/B:
3.94
Market Cap:
$ 1.44B
Enterprise V:
$ 1.22B
Volume:
110.76K
Avg Vol (2M):
266.73K
Also Trade In:
Volume:
110.76K
Market Cap $:
1.44B
PE Ratio:
At Loss
Avg Vol (2-Month):
266.73K
Enterprise Value $:
1.22B
PB Ratio:
3.94
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Enanta Pharmaceuticals Inc
NAICS : 325412 SIC : 2835
500 Arsenal Street, Watertown, MA, USA, 02472
Description
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Name Current Vs Industry Vs History
Cash-To-Debt 15.46
Equity-to-Asset 0.88
Debt-to-Equity 0.05
Debt-to-EBITDA -0.14
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 18.39
Distress
Grey
Safe
Beneish M-Score -1.31
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -21.6
3-Year Book Growth Rate -0.9
Name Current Vs Industry Vs History
5-Day RSI 95.99
9-Day RSI 89.25
14-Day RSI 82.95
6-1 Month Momentum % -13.76
12-1 Month Momentum % 17.64

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 11.12
Quick Ratio 11.12
Cash Ratio 9.12
Days Sales Outstanding 89.05

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.4

Financials (Next Earnings Date:2022-08-08)

ENTA's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ENTA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 91.563
EPS (TTM) ($) -5.52
Beta 0.41
Volatility % 85.65
14-Day RSI 82.95
14-Day ATR ($) 3.885349
20-Day SMA ($) 55.089
12-1 Month Momentum % 17.64
52-Week Range ($) 37.59 - 102
Shares Outstanding (Mil) 20.71

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Enanta Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More